1Meta-Analysis2008
Chrubasik C, Black A, Müller-Ladner U, Chrubasik S · Phytomedicine (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
19 peer-reviewed studies
What the evidence says
Most Devil's Claw studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1999–2026 with a typical study size of 88 participants.
Based on 19 studies · 3 meta-analyses · 8 RCTs · 88 total participants
Confidence
High confidenceBy outcome
5 studies in the last 5 years · Latest meta-analysis: 2017
Chrubasik C, Black A, Müller-Ladner U, Chrubasik S · Phytomedicine (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Del Grossi Moura M, Lopes LC, Biavatti MW, Kennedy SA, de Oliveira E Silva MC, Silva MT · Phytother Res (2017)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Oltean H, Robbins C, van Tulder MW, Berman BM, Bombardier C, Gagnier JJ · Cochrane Database Syst Rev (2014)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Vlachojannis J, Roufogalis BD, Chrubasik S · Phytother Res (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Gagnier JJ, Oltean H, van Tulder MW, Berman BM, Bombardier C, Robbins CB · Spine (Phila Pa 1976) (2016)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Brendler T, Gruenwald J, Ulbricht C, Basch E · J Herb Pharmacother (2006)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Gagnier JJ, Chrubasik S, Manheimer E · BMC Complement Altern Med (2004)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H · Eur J Anaesthesiol (1999)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Leblan D, Chantre P, Fournié B · Joint Bone Spine (2000)
No plain-language summary recorded for this citation — open the paper to read its abstract.
González-Gross M, Quesada-González C, Rueda J, Sillero-Quintana M, Issaly N, Díaz AE · Int J Environ Res Public Health (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
· Prescrire Int (2013)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chrubasik S, Model A, Black A, Pollak S · Rheumatology (Oxford) (2003)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Göbel H, Heinze A, Ingwersen M, Niederberger U, Gerber D · Schmerz (2001)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B · Phytomedicine (2000)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: By integrating molecular targets, preclinical and clinical evidence, and advances in delivery technologies, this review positions harpagoside as a prototype multi-target phytochemical with significant translational promise in inflammatory, metabolic, and degenerative disorders.
Kaur H, Kumar D, Gauttam VK, Suttee A, Kaur R, Tanwar R, Kondaveeti SB, Choudhary N. · Fitoterapia (2026)
In plain English: Such findings highlight the gaps in the study of these plants for the treatment of neurodegenerative diseases and, at the same time, the potential for opening new perspectives in the treatment of neurodegenerative diseases, providing expectations for innovative solutions in this critical domain of medicine.
Vital Júnior AC, da Silva MB, Monteiro SS, Pasquali MAB. · Pharmaceuticals (Basel, Switzerland) (2024)
In plain English: Further large-scale, rigorously designed randomized trials using standardized formulations are required.
Hong JY, Lee J, Kim H, Kim H, Jeon WJ, Yeo C, Lee YJ, Go HY, Ha IH. · Frontiers in pharmacology (2026)
In plain English: Our study confirmed that a combination of boswellic acid and harpagosides is beneficial as an additional therapy in knee OA.
Bender T, Somogyi P, Gógl Á, Sebők E, Gruber G, Hodosi K, Nemes K. · Journal of medicinal food (2024)
In plain English: Limited evidence was found for the Chinese plant extract duhuo jisheng Wan, cetyl myristoleate, lipids from green-lipped mussels, and plant extracts from Harpagophytum procumbens.
Ameye LG et al. · Arthritis research & therapy (2006)